Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors.
about
How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?Haploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic DisordersModern approaches to HLA-haploidentical blood or marrow transplantationAlternative Donor Transplantation for Acute Myeloid LeukemiaSome aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversyGraft versus host disease: New insights into A2A receptor agonist therapyFOXP3+ regulatory T cells and their functional regulationImproving the safety of cell therapy with the TK-suicide geneReconstitution and clinical significance of T cell subsets in the early stage after related HLA-mismatched peripheral blood hematopoietic SCT without T-cell depletion in vitro.Optimization of adipose tissue-derived mesenchymal stem cells by rapamycin in a murine model of acute graft-versus-host disease.High proportions of regulatory T cells in PBSC grafts predict improved survival after allogeneic haematopoietic SCT.Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia.Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplantAntithymocyte globulin improves the survival of patients with myelodysplastic syndrome undergoing HLA-matched unrelated donor and haplo-identical donor transplants.Strategies to accelerate immune recovery after allogeneic hematopoietic stem cell transplantation.Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?Lower incidence of acute GVHD is associated with the rapid recovery of CD4+CD25+CD45RA+ regulatory T cells in patients who received haploidentical allografts from NIMA-mismatched donors: A retrospective (development) and prospective (validation) cohFoxp3, Regulatory T Cell, and Autoimmune Diseases.Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO).New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood TransplantationTracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory.Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients.Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall.Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant.Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia.Combination Therapy Is the New Gene Therapy?Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients.The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation.Haploidentical HSCT: a 15-year experience at San Raffaele.Advances in haploidentical stem cell transplantation for hematologic malignancies.A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants.
P2860
Q26748867-BE284FF5-F8DA-4247-9424-FFC3697F0320Q26767501-A75628E9-6842-43E9-8320-C462ECD85B14Q26797506-D6138625-4487-4C0A-AF32-EB40C4D65D90Q26799456-4A0940F7-4E58-4EC2-A186-0455705689B3Q27010653-101A2AEA-62BC-489C-82B5-3717C0AB7D06Q28080809-979E6966-7A33-4E0C-BE98-C55EE1B1467AQ28082397-64AEC324-0701-4DDB-98F4-435082D9C8D5Q34477411-C255D4C3-F8C1-4642-BE16-B95924565A5DQ36095082-B45F2976-F9B3-4AC0-ADC0-1D921C77F2DDQ36202472-744E51CF-DDC4-4A16-8CED-E5C18A1BCDB8Q36442493-6D58521F-178C-4DB7-91C6-69DE8E873E12Q36687119-1C44E1EB-0B29-442B-B926-B33AF690C150Q37595693-290C7E8A-F055-44AD-B1CF-CB37797ACD5EQ37618811-2EFD530B-6A6F-4EA5-BC20-F8E8667394F4Q37618840-1BF8D388-A9A9-4AC0-9895-6ADD0AFF2086Q37681792-12310EE2-F45F-4571-BDF0-CC2FCDA47435Q38640239-6508C7F7-C0F4-49BB-A1FA-C6FE0214D076Q38742863-FF4BBE72-ED50-4709-A76C-64F519001CE7Q38970849-D283BF13-B5DE-495C-9D80-15D08AA95E52Q39018591-0067E3E0-B909-4C33-8353-714F1389030BQ39031946-A31A4AC2-E732-4BE2-8F01-FC1C94E24583Q39307476-F4455F32-AFB2-44FE-8683-27562CA0726AQ40577820-0E33C1AB-BE66-4E53-ADFC-3F58382DFBDFQ40874040-61C9BDF0-403F-4B81-A300-BE3AD9CD2DD1Q41008103-B01C8643-022D-418C-8DF3-40A843D2CAF3Q45795174-90B8C3A4-F8AD-4890-ADFD-66701795CC77Q45876839-76EEF427-314A-4176-86BC-478562D8D71CQ47952891-FD079FB0-6607-4D16-960A-ED7612A68526Q48199548-2F6A9E16-1B6E-474E-873E-8AA7E612C37FQ49608243-B5198FDB-7DF5-46DE-97F7-0E3CF0136B49Q49954477-0D0150B8-46A3-4524-8B8C-FF88F198BA37Q50042370-E48BA824-32F2-48D7-91E8-86F5491DC06DQ50548477-BE6142A1-E24A-46A0-B35F-5B55FE768900Q51636737-7CBD956D-099F-4152-AB12-D6EC411E18DEQ54216691-FA7E7AC4-A33C-4E56-A212-801FE5700822
P2860
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Sirolimus-based graft-versus-h ...... on from haploidentical donors.
@en
Sirolimus-based graft-versus-h ...... on from haploidentical donors.
@nl
type
label
Sirolimus-based graft-versus-h ...... on from haploidentical donors.
@en
Sirolimus-based graft-versus-h ...... on from haploidentical donors.
@nl
prefLabel
Sirolimus-based graft-versus-h ...... on from haploidentical donors.
@en
Sirolimus-based graft-versus-h ...... on from haploidentical donors.
@nl
P2093
P2860
P50
P356
P1433
P1476
Sirolimus-based graft-versus-h ...... ion from haploidentical donors
@en
P2093
A Assanelli
A Bondanza
C Bordignon
P2860
P2888
P304
P356
10.1038/LEU.2014.180
P577
2014-06-04T00:00:00Z
P5875
P6179
1002178386